TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics has announced significant changes to its Board and Executive management team to support its growth ambitions. Dr. Rohan Hockings has been re-appointed as Managing Director, and Prof. Ian Constable joins as a Non-Executive Director, bringing extensive experience in drug development. These changes are part of PYC’s strategy to advance its pipeline of drug candidates into late-stage clinical development, preparing for substantial growth and multiple concurrent clinical programs.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. The company leverages its proprietary drug delivery platform to enhance the effectiveness of precision medicines, particularly targeting monogenic diseases, which have a higher likelihood of success in clinical development.
Average Trading Volume: 886,850
Technical Sentiment Signal: Sell
Current Market Cap: A$522M
For a thorough assessment of PYC stock, go to TipRanks’ Stock Analysis page.